CoChat

Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus

Hirshberg, Boaz, Parker, Artist, Edelberg, Helen, Donovan, Mark, Iqbal, Nayyar · 2014 · Diabetes/Metabolism Research and Reviews
Cited by 55

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background: A post hoc pooled analysis was undertaken to evaluate the safety of saxagliptin in patients with type 2 diabetes mellitus, with attention to events of special interest for dipeptidyl peptidase‐4 inhibitors. Methods: Pooled analyses were performed for 20 randomized controlled studies (N = 9156) of saxagliptin as monotherapy or add‐on therapy, and a subset of 11 saxagliptin + metformin studies. Adverse events and events of special interest (gastrointestinal adverse events, infections, hypersensitivity, pancreatitis, skin lesions, lymphopenia, thrombocytopenia, hypoglycaemia, bone fracture, severe cutaneous adverse reactions, opportunistic infection, angioedema, malignancy, worsening renal function, and specific laboratory events) were assessed; incidence rates (events/100 person‐years) and incidence rates ratios (saxagliptin/control) were calculated (Mantel–Haenszel method). Results: In both pooled datasets, the incidence rates for deaths, serious adverse events, discontinuations due to adverse events, pancreatitis, malignancy, and most other events of special interest, excepting bone fractures and hypersensitivity, were similar between treatments, with 95% confidence intervals (CIs) for incidence rates ratios including 1. In the 20‐study pool, the incidence rates per 100 person‐years was higher with saxagliptin versus control for bone fractures [1.1 vs 0.6; incidence rates ratio (95% CI), 1.81 (1.04–3.28)] and hypersensitivity adverse events [1.3 vs 0.8; 1.67 (1.01–2.87)]. Conclusions: Pooled data from 20 studies confirm that saxagliptin has a favourable safety and benefit–risk profile. Copyright © 2013 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.2502

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 55

Metadata

Authors
Hirshberg, B., Parker, A., Edelberg, H., Donovan, M., & Iqbal, N.
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2014-10
Volume
30
Issue
7
Pages
556-569
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W1486033897
Cited by
55
References
6
FWCI
5.42
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1002/dmrr.2502
The paper
Hirshberg, B., Parker, A., Edelberg, H., Donovan, M., & Iqbal, N. (2014). Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.2502

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.